Physician profile
Violet Gray
NPI 1659084689
$9,179.90
in general payments reported to CMS, 2019-2025
66 companies · $3,187 in 2025
The $3,187 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,294 · 2024: $3,699 · 2025: $3,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,555 · Long Term Medical Supply Or Device Loan: $1,363 · Education: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,554.89 |
| Long Term Medical Supply Or Device Loan | $1,363.06 |
| Education | $261.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,992.99 | 2023-2025 | Kisqali, Piqray |
| Merck Sharp & Dohme LLC | $465.25 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Gilead Sciences, INC. | $456.21 | 2023-2025 | Trodelvy |
| Pfizer INC. | $429.00 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $345.86 | 2023-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Incyte Corporation | $342.14 | 2023-2025 | Jakafi, Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $328.72 | 2023-2025 | Opdivo, Opdualag |
| Celgene Corporation | $304.63 | 2023-2025 | Reblozyl, Opdualag, Pomalyst |
| Daiichi Sankyo INC. | $263.98 | 2023-2025 | Enhertu, Injectafer |
| Astrazeneca Pharmaceuticals Lp | $249.76 | 2023-2025 | Enhertu, Calquence, Imfinzi |
| Seagen INC. | $243.72 | 2023-2025 | Tukysa, Adcetris, Padcev |
| Astellas Pharma US INC | $224.39 | 2024-2025 | Padcev, Vyloy |
| Eisai INC. | $215.01 | 2023-2025 | |
| Janssen Biotech, INC. | $203.92 | 2023-2025 | Rybrevant, Darzalex, Tecvayli |
| Lilly USA, LLC | $201.65 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $201.07 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Abbvie INC. | $168.15 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $153.53 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $150.43 | 2023-2025 | Ultomiris |
| Sobi, INC | $124.88 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $119.75 | 2024-2025 | Libtayo |
| Array Biopharma INC | $117.51 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Taiho Oncology, INC. | $115.02 | 2024-2025 | |
| Beigene USA, INC. | $111.60 | 2023-2025 | Brukinsa |
| Genentech USA, INC. | $111.33 | 2023-2025 | Polivy, Tecentriq, Phesgo |
| Blueprint Medicines Corporation | $105.79 | 2023-2025 | Ayvakit |
| Stemline Therapeutics INC. | $97.20 | 2024-2025 | Orserdu |
| Tersera Therapeutics LLC | $83.94 | 2023-2025 | Zoladex |
| Pharmacosmos Therapeutics INC. | $71.91 | 2024-2025 | Monoferric, Cosela |
| Emd Serono, INC. | $58.90 | 2023-2025 | Bavencio |
| Genzyme Corporation | $55.90 | 2023 | |
| Servier Pharmaceuticals LLC | $52.13 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $51.27 | 2023 | Tavalisse, Rezlidhia |
| Exelixis INC. | $49.67 | 2023-2024 | Cabometyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.96 | 2023-2024 | Gilotrif |
| Pharmaessentia USA Corporation | $47.33 | 2024-2025 | Besremi |
| Adaptive Biotechnologies Corporation | $46.51 | 2025 | Clonoseq |
| Genmab U.S., INC. | $46.07 | 2023-2024 | Epkinly |
| Morphosys, US INC. | $41.59 | 2023 | Monjuvi |
| Agios Pharmaceuticals, INC. | $40.30 | 2023-2025 | Pyrukynd |
| Amgen INC. | $39.56 | 2023 | Lumakras |
| Foundation Medicine, INC. | $38.79 | 2023 | |
| Sumitomo Pharma America, INC. | $35.48 | 2023-2024 | Orgovyx |
| Sun Pharmaceutical Industries INC. | $34.04 | 2025 | |
| Mirati Therapeutics, INC. | $32.30 | 2023-2024 | Krazati |
| Kite Pharma, INC. | $29.87 | 2025 | Yescarta |
| Kyowa Kirin, INC. | $28.17 | 2025 | |
| Argenx US, INC. | $27.96 | 2024 | Vyvgart Hytrulo, Vyvgart |
| Dendreon Pharmaceuticals LLC | $27.24 | 2023 | Provenge |
| Beone Medicines USA, INC. | $25.80 | 2025 | Brukinsa |
| Geron Corporation | $24.74 | 2025 | Rytelo |
| Acrotech Biopharma INC. | $24.42 | 2023 | Beleodaq |
| Exact Sciences Corporation | $24.20 | 2025 | Cologuard Collection Kit |
| Recordati_rare_diseases_inc. | $23.14 | 2025 | Enjaymo |
| Apellis Pharmaceuticals, INC. | $23.04 | 2023 | Empaveli |
| Ipsen Biopharmaceuticals, INC | $23.00 | 2025 | Onivyde |
| Karyopharm Therapeutics INC. | $21.68 | 2023 | Xpovio |
| Tolmar, INC. | $21.14 | 2023 | |
| Puma Biotechnology, INC. | $20.36 | 2025 | |
| Aveo Pharmaceuticals, INC. | $19.00 | 2023 | Fotivda |
| Cumberland Pharmaceuticals, INC. | $18.32 | 2024 | Sancuso |
| G1 Therapeutics, INC. | $17.09 | 2023 | Cosela |
| Deciphera Pharmaceuticals INC. | $16.95 | 2023 | Qinlock |
| Legend Biotech USA INC. | $16.02 | 2024 | |
| Epizyme, INC. | $15.78 | 2023 | Tazverik |
| Jazz Pharmaceuticals INC. | $14.84 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Violet Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.